Novo Nordisks Wegovy cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease
Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater…
New REDUCE-IT Analyses Presented at ESC 2025 Include Data Showing VASCEPA/VAZKEPA (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups
-- 2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl…
Abbott receives regulatory approval for the first denosumab biosimilar in Thailand, expanding access to bone disease treatment
Abbott's denosumab biosimilar is the first approved in Thailand, making advanced therapy for…
Baylor Genetics to Showcase RNA Sequencing Breakthroughs for Rare Disease Diagnosis at 2025 AGBT Precision Health Meeting
HOUSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Baylor Genetics, a clinical diagnostic…
A Life Rewritten: KFSHRC Treats Rare Disease After 22 Years of Specialized Care
RIYADH, Saudi Arabia, Aug. 24, 2025 (GLOBE NEWSWIRE) -- In a rare…
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjgrens disease
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are…
Seegene Launches STAgora, a New Platform for Infectious Disease Analytics
Real-time analytics that empower clinical decision-making and pandemic preparednessGlobal unveiling at ADLM 2025…
Lilavati Hospital Doctors Save Life of 78-Year-Old Woman with Serious Heart Disease
India's First Successful Transcatheter Transatrial Mitral Valve Replacement Surgery Performed at Lilavati…
Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical…
Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9…
